Memphasys (ASX:MEM) has signed a 12-month exclusive national supply agreement with Monash IVF Group for its Felix™ automated sperm selection system. This represents the largest commercial agreement for the technology to date and advances the company’s Australian commercialisation strategy.

🧬 Major commercial agreement secured: The agreement follows a decade-long collaboration between Memphasys and Monash IVF, including the pivotal Felix™ clinical trial completed in 2025, and enables immediate commercial deployment following Felix™’s inclusion on the Australian Register of Therapeutic Goods.
🏥 National rollout across IVF network: Felix™ will initially be deployed at two Monash IVF clinics before expanding across the group’s Australian network of 22 clinics, subject to successful completion of the rollout phase. Monash IVF conducted 12,085 stimulated IVF cycles in 2025.
📈 Recurring revenue and market expansion: The agreement provides a pathway for recurring revenue through the supply of Felix™ cartridges and consoles, while establishing Monash IVF as a key reference customer to support broader adoption across Australia and international markets.

“Executing this agreement with Monash IVF is a significant commercial milestone for Memphasys, validating both the clinical value of Felix™ and our commercialisation strategy.” - Marjan Mikel, Chair of the Commercialisation Committee at Memphasys

The Reserve Bank of Australia (RBA) just kept Australia’s key cash rate on hold at 4.35% and it’s being described as a “hawkish hold”.

In central-bank speak, there are hawks and doves. Doves want lower rates, they care about growth while hawks worry about inflation, and they`re ready to raise rates to crush it.

A hawkish hold is when the bank doesn`t move rates today but makes it clear that it`s leaning towards hiking next time. Next time you see "rates on hold," ask the real question: hawkish, or dovish? That one word will tell you what might be coming next.

#stocks #investing #rates #economy #money

AI company Anthropic was just forced by the US government to switch off its two most powerful new models, Fable 5 and Mythos 5. The US government seems to believe that in the wrong hands, these models could be cyber weapons and has banned access to the models by foreign nationals.

The move may also relate to the very public feud between Anthropic and the Pentagon that erupted earlier this year. Either way the timing is brutal because Anthropic is planning an IPO, and a government pulling your flagship new products overnight is the kind of risk investors hate.

#tech #AI #US #stocks #fintok

Archer Materials (ASX:AXE) has provided an update on its quantum technology strategy. It highlighted the company’s progress across quantum computing, quantum machine learning, sensing and semiconductor-enabled medical diagnostics, as well as its efforts to deliver a key qubit development milestone by the third quarter of calendar 2026.

⚛️ Qubit development and manufacturing scale-up: Archer Materials remains on track to demonstrate a working qubit by the third quarter of calendar 2026 and has progressed beyond laboratory-scale devices toward wafer-scale manufacturing. The company has completed initial full-wafer graphene manufacturing runs and commenced testing to support scalable semiconductor production.

🧠 Quantum machine learning milestone achieved: Archer Materials reported successful benchmarking of its quantum machine learning fraud detection project, with its quantum neural network demonstrating competitive performance on both quantum simulators and commercial quantum hardware through AWS Braket.

🚀 Strategic growth opportunities under review: Archer is assessing potential acquisitions, intellectual property opportunities and technology collaborations aligned with its quantum strategy. The company is currently in discussions with several technology companies and institutions regarding possible transactions, partnerships and IP opportunities, although no agreements have been finalised.

“Quantum technology is moving rapidly from a research theme into a strategic global industry. Archer has been building its quantum technology capability for many years. We are now seeing that strategy come together across qubit development, quantum sensing, quantum machine learning and semiconductor-enabled medical diagnostics.” - Archer Materials CEO

Space Exploration Technologies Corp (NASDAQ:SPCX) has become the largest IPO in history, and having floated SpaceX at around a $2 trillion valuation, the founder Elon Musk has himself become the world`s first trillionaire.

The spaceflight, telecommunications, and AI company lifted 19% on its first day of trade on the Nasdaq, showing that investors see SpaceX as more than just rockets but a key player in AI infrastructure, connectivity and data.

The blockbuster listing comes as fellow mega-tech giants OpenAI and Anthropic prepare to possibly go public, and with SpaceX`s multi trillion dollar valuation, this is why you`ll be hearing we`re in the era of “The Mega IPO”.

#elonmusk #IPO #SPCX #fintok #SpaceX

Oracle Corp (NYSE:ORCL) has reported record results as demand for AI and cloud computing continues to surge, generating US$19.2 billion in quarterly revenue, with its cloud infrastructure business almost doubling compared with a year ago.

As businesses around the world are spending billions on AI technology Oracle is becoming a major provider of the computing power behind it. This shows the AI boom is expanding beyond chipmakers to cloud companies, building and operating the infrastructure powering artificial intelligence.

#tech #AI #fintok #NYSE #wallstreet

Microba Life Sciences (ASX:MAP) has completed a $5 million share placement that will support its path to cashflow break-even. This as the company continues to accelerate growth across its diagnostics business and advance its therapeutics pipeline.

🧬 $5 million placement completed: The capital raise attracted strong support from institutional and sophisticated investors, including strategic shareholder Sonic Healthcare, which committed $1.5 million as part of the placement.
📈 Strong diagnostics growth continues: Microba Life Sciences reported 11 consecutive quarters of core testing sales growth, with core testing sales increasing 106% over the past 12 months, supported by growing healthcare clinic contracts in Australia and continued expansion in the United Kingdom.
🚀 Break-even pathway and new product catalyst: The company said the funding, combined with streamlined AI-enhanced operations, supports a pathway to company-wide cashflow break-even on a run-rate basis in calendar 2027, while a new category-defining testing product remains on track for launch in the third quarter of calendar 2026.

“This funding positions us to achieve group cashflow break-even on a run-rate basis in 2027 whilst continuing to accelerate core Diagnostics growth, delivery of a major new test release in Q3 CY26, and progress to partner our Therapeutic assets.” - Microba Life Sciences Chair Pasquale Rombola

Environmental Clean Technologies Limited (ASX:ECT) has commenced a strategic commercialisation review of its proprietary COLDry® technology, assessing a range of pathways to bring it to market and maximise shareholder value. COLDry is a low-temperature lignite processing technology capable of producing value-added products for applications including agriculture.

🌱 Commercialisation review underway: Environmental Clean Technologies has engaged RSM Corporate Australia to provide an independent assessment of potential commercialisation pathways for COLDry, including licensing opportunities, partnerships, alternative applications and commercial structures.
🏭 Expanding market opportunities: The review will examine both Environmental Clean Technologies’ existing commercial relationships and broader opportunities for COLDry.
🤝 Strategic partnerships under review: Environmental Clean Technologies will also assess its ongoing relationship with Zero Quest, which is developing fertiliser products incorporating COLDry technology, as part of the broader evaluation of future commercial opportunities.

“ECT has spent more than two decades developing COLDry and we believe the technology has reached an important stage in its commercial development. This review is intended to ensure the Board considers the full range of opportunities available to maximise value from the technology.” - Environmental Clean Technologies Executive Chairman Faldi Ismail